Machado_2022_RSC.Med.Chem_13_1644

Reference

Title : Pyrazolines as potential anti-Alzheimer's agents: DFT, molecular docking, enzyme inhibition and pharmacokinetic studies - Machado_2022_RSC.Med.Chem_13_1644
Author(s) : Machado V , Cenci AR , Teixeira KF , Sens L , Tizziani T , Nunes RJ , Ferreira LLG , Yunes RA , Sandjo LP , Andricopulo AD , de Oliveira AS
Ref : RSC Med Chem , 13 :1644 , 2022
Abstract :

Alzheimer's disease (AD) is a neurodegenerative disease that is characterized as the main dementia in the elderly. Eighteen pyrazolines were synthesized and evaluated for their inhibitory effects against acetylcholinesterase (AChE) in vitro. Possible interactions between pyrazolines and the enzyme were explored by in silico experiments. Compound 2B of the series was the most active pyrazoline with an IC(50) value of 58 nM. Molecular docking studies revealed two important Pi-Pi interactions with residues Trp 286 and Tyr 341. A correlation between the HOMO-1 surface and AChE inhibition was observed. ADMET assays demonstrated a good profile for compound 2B. From the abovementioned findings, a new avenue of compound 2B analogues could be explored to develop anti-AD agents.

PubMedSearch : Machado_2022_RSC.Med.Chem_13_1644
PubMedID: 36561075

Related information

Citations formats

Machado V, Cenci AR, Teixeira KF, Sens L, Tizziani T, Nunes RJ, Ferreira LLG, Yunes RA, Sandjo LP, Andricopulo AD, de Oliveira AS (2022)
Pyrazolines as potential anti-Alzheimer's agents: DFT, molecular docking, enzyme inhibition and pharmacokinetic studies
RSC Med Chem 13 :1644

Machado V, Cenci AR, Teixeira KF, Sens L, Tizziani T, Nunes RJ, Ferreira LLG, Yunes RA, Sandjo LP, Andricopulo AD, de Oliveira AS (2022)
RSC Med Chem 13 :1644